Jamshid Arjomand, PhD

Jamshid Arjomand is a neuroscientist with more than 15 years of pharmaceutical and biotechnology experience in chronic pain, neurodegeneration, neuromuscular disorders and human stem cell disease modeling. He comes to the FSHD Society from Genea Biocells, a San Diego-based biotechnology company where he served for five years as Vice President of Business Development. At Genea, he managed the scientific direction and collaborative efforts necessary to expand the company’s drug discovery efforts, internal R&D capabilities and revenue streams. Genea’s pipeline included FSHD for which their lead asset, GBC0905, received orphan drug designation by the FDA in May 2018.

From 2005 to 2013, Arjomand served as Director of Basic Research at CHDI Foundation. There he designed and managed a complex portfolio of academic, clinical and industry driven projects, primarily related to biomarker discovery, stem cell development, and target discovery and validation efforts for Huntington disease.